Navigation Links
Genesis Pharmaceuticals Announces Results for The First Quarter of Fiscal Year 2008
Date:11/19/2007

es and promote digestion. The Company expects revenue from Baobaole chewable tablets in the second quarter of fiscal year 2008 to exceed $1.8 million.

The increase in selling, general and administrative expenses was also caused by the Company hiring 70 additional sales executives to sell products to the rapidly growing Over-The-Counter pharmaceutical market in China.

Operating income for the first quarter of Fiscal Year 2008 totaled $4.9 million, an 8.7% decrease from $5.4 million in the first quarter of Fiscal Year 2007. The Company's operating margins decreased to 29.7% from 31.0% for the same periods.

Net income for the first quarter of Fiscal Year 2008 totaled $3.2 million, down 7.6% from net income of $3.5 million in the first quarter of Fiscal Year 2007.

Financial Condition

As of September 30, 2007, the Company had $4.6 million in cash and cash equivalents, $19.6 million in working capital and a current ratio of 2.1:1. The Company used $3.2 million in cash flow from operations in the first quarter of Fiscal Year 2008, partly due to a $3.9 million payment to raw material suppliers, hedging against anticipated rising prices for raw materials. As of September 30, 2007, the Company had $10.8 million of bank debt and bank notes, and $30.9 million of shareholders' equity.

Business Outlook

Genesis Pharmaceuticals Enterprises, Inc. is well positioned in the Chinese pharmaceutical industry with four drugs currently approved by the Chinese State Food and Drug Administration. The product launch of Baobaole chewable tablets is expected to add immediately to revenues and quickly develop significant market share. The Company is developing new products, some of which are awaiting government approvals.

The company has contracted to purchase the patent for Ligustrazine Ferulic Acid Acetate ("LFAA"), a Chinese Class 1 drug. LFAA is undergoing testing as a cardiac cerebral vascular medicine that is designed to help reduce blood clo
'/>"/>

SOURCE Genesis Pharmaceuticals Enterprises, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Pathway links inflammation, angiogenesis and breast cancer
2. EURYI project to understand how the brain wires during embryogenesis
3. DNA damage response confers a barrier for viral tumorigenesis
4. ThermoGenesis Announces 510(k) Clearance for AutoXpress(TM) Cord Blood Processing System
5. The genetics of MLL leukemogenesis
6. Genesis Technology Group Retains CCG Elite
7. Researchers chart the genetic mechanisms behind the genesis of fat cells
8. Tissue Genesis Signs Exclusive Distribution and License Agreement with SpineSmith
9. ThermoGenesis Corp. Reports First Quarter 2008 Results
10. Cardiogenesis Receives FDA Approval for PEARL 5.0 Robotic Hand Piece
11. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Oxnard, CA (PRWEB) September 30, 2014 ... the Anacapa Dental Art Institute in Oxnard and Thousand ... Bangalore today and tomorrow to provide training on full ... previous dental work, placing implants, providing cosmetic dentistry, correcting ... Dr. Jivraj said. , Dr. Jivraj, who has traveled ...
(Date:9/30/2014)... If you were to create a list ... it say? Would you place a high value on charisma? ... create a leadership “wish list,” the truth is that just ... there different types of leaders. But if good leaders come ... programs that account for this kind of diversity? , ...
(Date:9/30/2014)... Lexington, KY (PRWEB) September 30, 2014 ... million people in the United States alone have sleep ... treated; and of those treated, many cannot tolerate their ... pressure supplied through a nasal mask) – which supports ... good night’s sleep has become especially valuable, and increasingly ...
(Date:9/30/2014)... is proud to announce the release of The ... by Frank Guglielmo and Sudhanshu Palsule ... their leadership coaching experience to introduce Social Leadership – a ... that leaders must adopt in order to thrive in today’s ... review of The Social Leader in Dialogue Reviews. , Author ...
(Date:9/30/2014)... IL (PRWEB) September 30, 2014 ... clash,” opened Bryan W. Brickner, “and it’s about ... Political Cannabinoid Science , new on the Bryan ... research from the National Institutes of Health (PubMed). ... regarding: de-homeostatic sleep disturbances, REM transitions, aging with ...
Breaking Medicine News(10 mins):Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 2Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 3Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 4Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 5Health News:Personality Plays a Key Role in Leadership Development 2Health News:Personality Plays a Key Role in Leadership Development 3Health News:Snoring: Robs People and Their Bed Partners of the Rest They Need to Face Daily Challenges 2Health News:Snoring: Robs People and Their Bed Partners of the Rest They Need to Face Daily Challenges 3Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 2Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 3Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 4Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 5Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 6Health News:Homeostasis: Publius’ Sleep Political Cannabinoid Science ~ New on the Bryan William Brickner Blog 2
... to have their blood sugar, blood pressure, and cholesterol ... a high-quality Medicare plan, researchers reported Tuesday. ... Medical Association, show that racial disparities are common throughout ... Amal N. Trivedi of Brown University in Providence, Rhode ...
... about personalized medicine enabled through genetic testing, slated to ... would not only involve forecasting the presence of a ... but will also enable early prevention strategies. ... cardiovascular diseases, but will unravel the genetic blue prints ...
... of folic acid every day could have better chance of getting ... form of vitamin B is used in our bodies to make ... body before she is pregnant, it can help prevent major birth ... study involving more than 18,000 women for the first time revealed ...
... Regular exercise combined with nicotine replacement therapy could help ... colleagues at the Otto Wagner Hospital// in Vienna enrolled ... nicotine-replacement therapy, reported the online edition of health magazine ... be quitters enrolled in an exercise programme., ,The ...
... to a recent study, women with a twin are at upto ... without one//. ,The study was conducted on over 800 ... premature ovarian failure (POF) at the age of 40 was 3-5 ... causes the ovaries to shut down ten years or earlier than ...
... and toddlers, reports a major study conducted on the side effects ... government proposed immunization for all kids of the age 6 months ... a sharp rise in the number of children getting vaccinated. This ... 2 years as often as the old people. ,This ...
Cached Medicine News:Health News:Medicare Marked by Widespread Racial disparities 2Health News:Folic Acid Supplements Could Help Conception 2
(Date:9/30/2014)... 2014 China,s ... earthshaking changes. The country,s new leaders have recognized that ... reagents are far from perfect along with rapid population ... Chinese state council issued the latest "Regulations for the ... 2014, and it has come into force as June ...
(Date:9/29/2014)... and PARIS , Sept. 30, 2014 ... (EURONEXT: SAN and NYSE: SNY) today announced that a ... that blocks IL-4 and IL-13 signaling, met all primary ... with nasal polyps (CSwNP) who did not respond to ... potential of dupilumab for use in the treatment of ...
(Date:9/29/2014)... DUBLIN , Sept. 29, 2014  TNI ... biotechnology company pioneering the manufacturing both US and Internationally ... cancer, HIV/AIDS, opportunistic infections and autoimmune diseases in emerging ... Noreen Griffin The letter follows: Dear Shareholders, ... received a number of calls from shareholders and wants ...
Breaking Medicine Technology:Latest Chinese Guidebook for Application and Approval of Imported In-vitro Diagnostic Reagent Registration: From Regulations to Practices (2014 Edition) 2Latest Chinese Guidebook for Application and Approval of Imported In-vitro Diagnostic Reagent Registration: From Regulations to Practices (2014 Edition) 3Latest Chinese Guidebook for Application and Approval of Imported In-vitro Diagnostic Reagent Registration: From Regulations to Practices (2014 Edition) 4Latest Chinese Guidebook for Application and Approval of Imported In-vitro Diagnostic Reagent Registration: From Regulations to Practices (2014 Edition) 5Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 2Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 3Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 4Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 5Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 6Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 7TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 2TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 3TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 4TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 5TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 6TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 7TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 8
... 9, 2011 The "Scientific Oktoberfest" will be ... distinguished researchers in the field of Chemical Biology. The so-called ... from the 15 th to the 16 th ... (LMU) München. At the two-day conference, 400 researchers ...
... Holdings, Inc., (NYSE: HRC ) today announced ... Item SA and Liko Care AG, the distribution companies ... Switzerland.  Hill-Rom, the global leader in patient support solutions, ... acquisition of Liko, A.B., a leading provider of patient ...
Cached Medicine Technology:"Scientific Oktoberfest" Draws the Worldwide Leading Researchers in the Field of Chemical Biology to Munich 2Hill-Rom Acquires Liko France and Switzerland 2Hill-Rom Acquires Liko France and Switzerland 3
... system includes: Mx3005P instrument and custom ... five (5) filters. The standard filter ... HEX/JOE/VIC (535nm-555nm), ROX/Texas Red (585nm-610nm), Cy5 ... notebook computer, Mx3005P analysis software, Beacon ...
... SmartCycler System is a rapid, real-time thermal ... biological samples. By automating much of the ... individually programmable, it is the fastest, easiest ... on the market. The SmartCycler delivers highly ...
... SmartCycler System is a rapid, real-time thermal ... biological samples. By automating much of the ... individually programmable, it is the fastest, easiest ... on the market. The SmartCycler delivers highly ...
... The SmartCycler System is a rapid, real-time ... prepared biological samples. By automating much of ... site individually programmable, it is the fastest, ... now on the market. The SmartCycler delivers ...
Medicine Products: